IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures

MT Newswires Live

06/18

IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.

The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.

Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.

The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.

Price: 7.95, Change: +5.82, Percent Change: +273.24

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2644723293"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644723293\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644723293?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 02:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644723293","market":"sg","top_or_hot":-1,"title":"IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures","media":"MT Newswires Live","content":"<html><body><p> IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.</p><p>The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.</p><p>Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.</p><p>The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.</p><p>Price: 7.95, Change: +5.82, Percent Change: +273.24</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-18 02:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.</p><p>The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.</p><p>Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.</p><p>The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.</p><p>Price: 7.95, Change: +5.82, Percent Change: +273.24</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644723293","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644723293","pubTimestamp":1781719747,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"IceCure Medical  shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.Price: 7.95, Change: +5.82, Percent Change: +273.24","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ICCM":"IceCure Medical Ltd."},"translate_title":"乳腺癌冷冻消融手术商业采用的最新消息后，IceCure Medical股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":1.5},"content_text":"IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.Price: 7.95, Change: +5.82, Percent Change: +273.24","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}